Summit Therapeutics

Últimas notícias

Manchetes no idioma original da fonte.

• Summit Therapeutics Inc. plans Datroway Phase III trial (abre em uma nova aba)

  Mugglehead Investment Magazine · 2 de out. de 2026

• Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types (abre em uma nova aba)

  Investing News Network · 2 de out. de 2026

• AstraZeneca and Daiichi Sankyo Partner with Summit Therapeutics to Study Datopotamab Deruxtecan and Ivonescimab (abre em uma nova aba)

  Oncodaily · 2 de out. de 2026

• AstraZeneca, Daiichi Sankyo and Summit Therapeutics Plan Datroway–Ivonescimab Combination Trials (abre em uma nova aba)

  Yahoo Finance UK · 2 de out. de 2026

• AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (abre em uma nova aba)

  Reuters · 2 de out. de 2026

• AstraZeneca, Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway-ivonescimab combo (abre em uma nova aba)

  Seeking Alpha · 2 de out. de 2026

• AstraZeneca & Daiichi Sankyo announce clinical collaboration with Summit Therapeutics (abre em uma nova aba)

  TradingView · 2 de out. de 2026

• Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway (abre em uma nova aba)

  Business Wire · 2 de out. de 2026

• AstraZeneca and Daiichi Sankyo announce clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumour types (abre em uma nova aba)

  AstraZeneca · 2 de out. de 2026

• Summit Therapeutics Is Maintained at Equal-Weight by Barclays (abre em uma nova aba)

  Moomoo · 1 de out. de 2026

• What Does Summit Therapeutics (SMMT) Gain From This $2 Billion Cancer Partnership? (abre em uma nova aba)

  Yahoo Finance · 1 de out. de 2026

• Summit Therapeutics Price Target Raised to $20.00/Share From $18.00 by Barclays (abre em uma nova aba)

  Moomoo · 1 de out. de 2026

• Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Raises Target Price to $20 (abre em uma nova aba)

  Moomoo · 1 de out. de 2026

• Summit Therapeutics Stock Climbs Wednesday: What's Happening? (abre em uma nova aba)

  TradingView · 30 de set. de 2026

• AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets (abre em uma nova aba)

  24/7 Wall St. · 30 de set. de 2026

• Leerink Partners Sticks to Its Hold Rating for Summit Therapeutics (SMMT) (abre em uma nova aba)

  The Globe and Mail · 30 de set. de 2026

• H.C. Wainwright reiterates Summit Therapeutics stock rating as Neutral (abre em uma nova aba)

  Investing.com · 30 de set. de 2026

• Wells Fargo Reaffirms Their Buy Rating on Summit Therapeutics (SMMT) (abre em uma nova aba)

  The Globe and Mail · 30 de set. de 2026

• AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll (abre em uma nova aba)

  BioSpace · 30 de set. de 2026

• Citizens reiterates Summit Therapeutics stock rating after AstraZeneca deal (abre em uma nova aba)

  Investing.com · 30 de set. de 2026

• AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics (abre em uma nova aba)

  Oncodaily · 30 de set. de 2026

• AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up (abre em uma nova aba)

  Reuters · 30 de set. de 2026

• AstraZeneca Backing Could Change The Case For Summit Therapeutics Stock (abre em uma nova aba)

  Simply Wall Street · 29 de set. de 2026

• AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug (abre em uma nova aba)

  medcitynews.com · 29 de set. de 2026

• AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says (abre em uma nova aba)

  Yahoo Finance · 29 de set. de 2026

• Summit Therapeutics Rises as AstraZeneca Backs Ivonescimab With $2 Billion Investment (abre em uma nova aba)

  Quiver Quantitative · 29 de set. de 2026

• Summit Therapeutics: Stronger Balance Sheet Helps, But It Does Not De-Risk Ivonescimab (abre em uma nova aba)

  Seeking Alpha · 29 de set. de 2026

• AstraZeneca Stock Slips as $2 Billion Summit Stake Deepens Oncology (abre em uma nova aba)

  Yahoo Finance · 29 de set. de 2026

• Summit Shares Jump on $2B Strategic Investment From AstraZeneca (abre em uma nova aba)

  Yahoo Finance · 29 de set. de 2026

• AstraZeneca Makes $2B Equity Investment in Summit Therapeutics (abre em uma nova aba)

  Contract Pharma · 29 de set. de 2026